Sindhu Hospitals launches ‘BeyondA1C’ screening for diabetic complications

Metro India News | Hyderabad

Sindhu Hospitals, an initiative of Sai Sindhu Foundation, and BeyondA1C, a division of MedicaMetrix, Inc., signed a Memorandum of Understanding on Friday to launch ‘BeyondA1C’ testing at Sindhu Hospitals. The Sheffield One-Stop becomes its frontline mass screening test for diabetic complications, and regular BeyondA1C testing and could become a potential model for diabetic, dialysis and chemotherapy patients, in the first launch of these tests in India.

The AI enabled device can deliver testing for 3 key clinical scenarios: Sheffield One-Stop which is a screening test for people at risk of diabetes and suffering from established diabetes; beyondA1C Onco which measures sural nerve function in both legs for those undergoing chemotherapy;  and beyondA1C Dialysis through which patients who are on regular dialysis receive an IWGDF 2023 risk category from 0 to 3, so the nephrologists can initiate early intervention.

Robert Rudelius, Chief Executive Officer, MedicaMetrix mentioned that the commitment of Sindhu Hospitals to research will show what earlier testing means for patients with diabetes, cancer and kidney disease. B. Soma Raju, Consultant Cardiologist and Mentor Director, Sindhu Hospitals said that BeyondA1C tests will become part of our specialties, including oncology and dialysis.